Showing 3121-3130 of 4264 results for "".
- Soliton Names New President and CEOhttps://practicaldermatology.com/news/soliton-names-new-president-and-ceo/2460593/Brad A. Hauser is the new President and Chief Executive Officer of Soliton. He most recently served as Vice President, R&D and General Manager for CoolSculpting at Allergan Aesthetics, an AbbVie Company, since Allergan's April 2017
- Data Confirm Efficacy, Safety of Nutrafol for Menopausal Womenhttps://practicaldermatology.com/news/data-confirm-efficacy-safety-of-nutrafol-for-menopausal-women/2460563/Administration of Nutrafol’s Women’s Balance formulationis safe and effective in improving hair growth and quality in women going through menopausal transition, according to new data. Presented in a poster presentation at the Annual Meeting of the American Society for D
- It's a Deal: Allergan Buys Luminera Dermal-Filler Businesshttps://practicaldermatology.com/news/its-a-deal-allergan-buys-luminera-dermal-filler-business/2460556/Allergan Aesthetics, an AbbVie company, has acquired Luminera's full dermal filler portfolio and R&D pipeline. Luminera is a privately held aesthetics company based in Israel with a portfolio and pipeline of dermal filler products. "
- AOBiome Initiates Phase 2b Clinical Trial of B244 in Adults with ADhttps://practicaldermatology.com/news/aobiome-initiates-phase-2b-clinical-trial-of-b244-in-adults-with-ad/2460450/AOBiome Therapeutics, Inc. is initiating a Phase 2b clinical trial of its lead product candidate, B244, in pruritus associated with atopic dermatitis. B244 is a first-in-class, topical formulation of beneficial ammonia oxidizing bacteria that is delivered as a spray twice daily for 28 d
- Kubota Vision, LEO Pharma A/S to Screen Novel VAP-1 Inhibitors for Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases/2460351/Kubota Vision Inc. signed an Open Innovation Agreement with LEO Pharma A/S to screen novel Vascular Adhesion Protein-1 (VAP-1) inhibitor compounds for potential therapeutic use in inflammatory skin diseases, such as psoriasis and atopic dermatitis. During R&D activities to develop n
- Aerolase and Eucerin Join Forces to Optimize Patient Outcomes in Laser Treatmentshttps://practicaldermatology.com/news/aerolase-and-eucerin-join-forces-to-optimize-patient-outcomes-in-laser-treatments-1/2460277/Aerolase and Eucerin are working together to optimize laser treatment protocols in the D-A-CH-region (Germany-Austria-Switzerland). Furthermore, both companies will develop therapies for adjunctive care post-laser treatments. Both companies will also conduct a joint symposium
- LEO Science & Tech Hub and Epicore Biosystems Advance AD Collabhttps://practicaldermatology.com/news/leo-science-tech-hub-and-epicore-biosystems-advance-ad-collab/2460208/LEO Science & Tech Hub, the Boston-based R&D innovation unit of LEO Pharma A/S, is starting the next phase of a research collaboration in atopic dermatitis (AD) with Epicore Biosystems, a wearable microfluidics and biosensor spinout from Northwestern University’s Center for Bio-Inte
- Hair Loss Breakthrough: 3D-Printing Creates “Hair Farms”https://practicaldermatology.com/news/hair-loss-breakthrough-research-uses-3d-printing-to-create-hair-farms/2460083/Columbia researchers have created a way to use 3-D printing to create “hair farms” in a dish, which could open up hair restoration surgery to more people, including women, and improve the way pharmaceutical companies search for new hair growth drugs. The findings, which appe
- Skin Metabolomics: Estee Lauder Presents New Research at WCDhttps://practicaldermatology.com/news/skin-metabolomics-estee-lauder-presents-new-research-at-wcd/2460063/The Estée Lauder Companies Inc.Research & Development (R&D) team will present data focused on new findings in skin metabolomics, skin defense, ingredient science, and anti-aging research at the 2019 World Congress of Dermatology (WCD) in Milan, Italy from June 10 -15.
- LEO Pharma and Advancing Innovation in Dermatology Partner to Help Finance Accelerator Fundhttps://practicaldermatology.com/news/leo-pharma-and-advancing-innovation-in-dermatology-partner-to-help-finance-accelerator-fund/2457713/LEO Pharma and its Boston-based R&D innovation unit LEO Science & Tech Hub, and Advancing Innovation in Dermatology (AID) will each contribute $500,000 into the recently created Advancing Innovation in Dermatology Accelerator Fund. This non-profit fund is unique in its approach for suppor